Study Complete
Sponsor ID
20110174

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) versus Placebo in Men with OsteoporosisBRIDGE

Sponsor ID
20110174
Clinicaltrials.gov ID
NCT02186171
EUCTIS ID
N/A
EudraCT ID
2013-005551-32

Study Details

The study is designed to evaluate if treatment with romosozumab once a month for 12 months compared with placebo is effective in increasing bone mineral density (BMD) at the lumbar spine. Additionally, the study will assess the effect of treatment with romosozumab for 12 months compared with placebo on BMD at the femoral neck and total hip.

Additional Study Details

Phase
Phase 3
Product
AMG 785
Type
Interventional
Masking
Triple (Participant, Care Provider, Investigator)
Enrollment
245
Additional Study Details

Protocol Summary

Primary Outcome Measures

Percent change from baseline in DXA BMD at the lumbar spine at Month 12

Timeframe: 12 Months

Secondary Outcome Measures

Percent change from baseline in DXA BMD at the femoral neck and total hip at Month 12.

Timeframe: 12 Months

Percent change from baseline in DXA BMD at the lumbar spine, femoral neck, and total hip at Month 6.

Timeframe: Month 6

Study Documents

Study Synopsis
Available Language(s): English

Locations

Location
Status
Contact Us
Location
Research Site
Bethesda, MD, United States, 20817
Status
Recruiting
Location
Research Site
Lakewood, CO, United States, 80227
Status
Recruiting
Location
Research Site
Shinagawa-ku, Tokyo, Japan, 140-0011
Status
Recruiting
Location
Research Site
Albuquerque, NM, United States, 87106
Status
Recruiting
Location
Research Site
Bungoono-shi, Oita, Japan, 879-7125
Status
Recruiting
Location
Research Site
Mizunami-shi, Gifu, Japan, 509-6134
Status
Recruiting
Showing {first} - {last} of {total} Results